New drug trial targets lung Cancer's genetic weakness
NCT ID NCT05463224
Summary
This study is testing a medication called lazertinib as the first treatment for adults with advanced non-small cell lung cancer that has specific EGFR genetic mutations. The trial aims to see how well the drug controls the cancer and how safe it is, while also trying to understand why the cancer might eventually stop responding to the drug. Participants will take the drug daily and provide tissue and blood samples to help researchers learn about resistance.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Samsung Medical Center
Seoul, Gangnamgu, 06351, South Korea
Conditions
Explore the condition pages connected to this study.